IKIrina E. Kravchenko

Irina E. Kravchenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Irina E. Kravchenko has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Alterations of phospholipid fractions in patients with HIV/tuberculosis coinfection under different treatment regimens

    by Irina E. Kravchenko, Pavel V. Makarov, Sergey V. Starikov, Oleg V. Nozdrevatykh, Elena A. Chaynikova

    BACKGROUND: Alterations in phospholipid fraction balance represent one of the mechanisms underlying lipid metabolism disorders in HIV infection. AIM: To investigate the dynamics of phospholipid fractions in patients with HIV/tuberculosis coinfection undergoing monotherapy with antitubercular agents versus combined antiretroviral and anti-tuberculosis therapy. MATERIAL AND METHODS: A comparative study of phospholipid fractions (sphingomyelin, phosphatidylcholine, lysophospholipids, phosphatidylethanolamine) was conducted using chromatography in two groups of patients with HIV-associated tuberculosis: Group 1 (100 patients) received tuberculosis chemotherapy (isoniazid, rifampicin, pyrazinamide, ethambutol), while Group 2 (100 patients) received antiretroviral therapy (tenofovir, lamivudine, efavirenz) alongside treatment with antitubercular agents. The control group consisted of 50 healthy individuals. CD4 lymphocyte counts and HIV RNA viral load were measured in all patients. Assessments were performed before treatment initiation and after 1 and 2 months of therapy. Statistical analysis was conducted using parametric methods, with differences considered significant at p 0.05. RESULTS: Before treatment initiation, both groups of patients with HIV/tuberculosis coinfection had higher levels of sphingomyelin, lysophospholipids, and phosphatidylcholine compared to healthy individuals (p=0.001). In Group 1, receiving only anti-tuberculosis therapy, levels of sphingomyelin, lysophospholipids, and phosphatidylcholine significantly increased (p=0.001), with no change in the number of patients exhibiting bacterial shedding. In Group 2, after one month of antiretroviral therapy combined with anti-tuberculosis treatment, levels of sphingomyelin, lysophospholipids, and phosphatidylcholine decreased below those of the control group (p=0.001). A significant reduction in patients with bacterial shedding was observed (from 100% to 18%, p=0.001). CONCLUSION: In the group of patients receiving combined antiretroviral and anti-tuberculosis therapy, a reduction in sphingomyelin and lysophospholipid levels was observed, along with a decrease in the number of patients exhibiting bacterial shedding.

  • Open Access

    Evaluation of the efficacy and safety of the drug Raphamin in the treatment of influenza in adults and children aged 12–18 years: analysis of the results of randomized clinical trials

    by A.V. Gorelov, A.A. Zaytsev, Ministry Of Defense Of The Russian Federation Main Military Clinical Hospital Named After Academician N.N. Burdenko, A.G. Malyavin, E.V. Esaulenko, I.E. Kravchenko, V.V. Nikiforov, D.V. Usenko, S.L. Babak, K.E. Novak, et al.

    Оценка эффективности и безопасности препарата Рафамин в терапии гриппа у взрослых и детей 12-18 лет: анализ результатов рандомизированных клинических

  • Open Access

    The effect of etiopathogenetic therapy of COVID-19 on the severity of the disease: results of a multicenter double-blind placebo-controlled randomized trial

    by Vladimir V. Nikiforov, Vladimir A. Petrov, Anatoly A. Stremoukhov., Marina G. Avdeeva, Yury G. Shvarts, Irina E. Kravchenko, Irina V. Nikolaeva, Svetlana E. Ushakova, Oksana N. Belousova, Natal'IA A. Eremina, et al.

    Aim. The search for etiopathogenetic agents to prevent the development of severe and extremely severe COVID-19 remains relevant. A placebo-controlled randomized clinical trial was conducted to evaluate the efficacy and safety of the antibody-based biological drug (Raphamin).Materials and methods. 785 outpatients 18–75 y.o. with laboratory confirmed mild COVID-19 were included within 24 hours from the disease onset. 771 patients were randomized to the group Raphamin (n=382) and the Placebo group (n=389). The study drug/placebo was prescribed for 5 days. The rate of progression to a more severe degree of COVID-19 by day 28 as well as the time to sustained clinical recovery and the frequency of hospitalization were evaluated. Safety was assessed taking into account adverse events, vital signs and laboratory parameters.Results. The number of cases of progression to a more severe degree of COVID-19 in participants receiving Raphamin was 59 (15.5%) [52 (14.6%)] versus placebo – 89 (22.9%) [85 (23.7%)], ITT and [PP] analysis data are presented. The odds ratio between groups was OR=0.6157 [OR=0.5494], 95% confidence interval 0.4276–0.8866 [0.3750–0.8048], which meant a reduction in the chance of progression to a more severe degree by 38.4% [45.1%] or 1.48 [1.62] times; p=0.0088 [p=0.0019]. The time to sustained recovery in the Raphamin group was 4.5±2.4 [4.6±2.4] days, versus placebo – 5.8±4.7 [6.0±4.8] days; p=0.0025 [p=0.0036]. No adverse events with a certain relationship were registered.Conclusion. Raphamin reduces the risk of progression to a more severe degree of the COVID-19 and significantly shortens the duration of clinical symptoms.

  • Open Access

    Non-specific prevention of COVID-19 during vaccination against a new coronavirus infection: results of a multicenter, double-blind, placebo-controlled, randomized clinical trial

    by M G Avdeeva, O N Belousova, E A Orlova, R F Khamitov, Y G Shvarts, I E Kravchenko

    Background. A multicenter, double-blind, placebo-controlled, randomized clinical trial (RCT) of the phase III efficacy and safety of Ergoferon for the non-specific prevention of COVID-19 during vaccination against a new coronavirus infection was conducted (permission of the Ministry of Health of the Russian Federation №559 dated 22.09.2021; ClinicalTrials.gov Identifier: NCT05069649). Aim. To evaluate the efficacy and safety of the use of Ergoferon for the non-specific prevention of COVID-19 during vaccination against a new coronavirus infection. Materials and methods. From October 2021 to April 2022, 1,057 patients aged 18 to 92 years who received component I of the Gam-COVID-Vac vaccine were included. After screening, 1,050 patients were randomized into 2 groups: 526 people received Ergoferon according to the prophylactic scheme 1 tablet per administration 2 times a day for 3 weeks, the drug is not allowed during the meal and should be kept in the mouth without swallowing, until completely dissolved; 524 patients received a placebo according to the Ergoferon scheme. The total duration of participation in the study was 5 weeks + 3 days. The primary endpoint is the number of RT-PCR confirmed cases of SARS-CoV-2 infection, regardless of the presence of symptoms during participation in the study. An additional criterion of effectiveness is the proportion of those hospitalized with COVID-19. The safety assessment included consideration of the presence and nature of adverse events (AEs), their severity, relationship with the drug intake, and outcome. Statistical data processing was carried out using SAS 9.4 with the calculation of the exact Fisher test, 2 test, CochraneMantelHensel test, Wilcoxon test and other parameters. Results. The ITT (Intention-to-treat) and PP [Per Protocol] efficacy analysis included data from 1,050 [970] patients: 526 [489] people Ergoferon group and 524 [481] people Placebo group. The primary endpoint the number of laboratory-confirmed cases of SARS-CoV-2 infections was 3 times less compared to placebo 7 (1.43%) vs 22 (4.57%), respectively (p=0.0046; [p=0.0041]). Taking Ergoferon reduces the risk of SARS-CoV-2 infection by more than 3 times in vaccinated patients during 5 weeks of the vaccination and post-vaccination periods (p=0.0046 [p=0.0041]). Of the COVID-19 patients in the Ergoferon group (1.33%) nobody was hospitalized. According to the Post hoc analysis, Ergoferon reduces the risk of COVID-19 disease by 4 times in the period between the components I and II of the Gam-COVID-Vac vaccine (p=0.0066 [p=0.006]). The frequency of AEs in both groups did not differ. There were no registered AEs associated with the drug with a reliable degree. There was a high level of patient compliance and good tolerability. Conclusion. Ergoferon is an effective and safe drug for the prevention of COVID-19 in people vaccinated against a new coronavirus infection.


  • Infectious morbidity of the population and resource provision infectious disease service: relationships, challenges and proposals

    by Kazan State Medical University, I.E. Kravchenko, G.E. Ulumbekova, A.M. Galieva, A.Yu. Vafin, Moscow Direct Prime Llc, R.G. Turaev, Kazan State Medical Academy – Branch Of The Russian Medical Academy Of Continuing Professional Education

    Инфекционная заболеваемость населения РФ и ресурсное обеспечение инфекционной службы: взаимосвязи, вызовы и предложения


  • Open Access

    Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020

    by Natalia Yu. Pshenichnaya, Elena N. Kareva, Irina A. Leneva, Vilya A. Bulgakova, Irina E. Kravchenko, Irina V. Nikolaeva, Antonina I. Grekova, Antonina P. Ivanova, Larisa V. Puzyreva, Guzel M. Khasanova, et al.

    Aim. An analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness. Materials and methods. The study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions of Russia. The number of men and women was equal, mean age 48.718.1 (median 50). Patients with moderate COVID-19 (85%) versus mild COVID-19 (15%) were characterized by higher age (median 54 vs 21 years; p0.001), higher body mass index (27.8 vs 23.4; p0.001), prevalence of chronic diseases (75.3% vs 8.5%; p0.001), including circulatory system diseases (37.8%). Moderate COVID-19 characterized higher intoxication (10.86.1 vs 4.22.7 days; p0.001) and catarrhal symptoms duration (10.25.4 vs 6.14.1 days; p0.001). Results. During hospitalization 92% of the patients received AVT, 77% antibiotics, and 16% corticosteroids. Umifenovir therapy resulted in a significant reduction of intoxication (8.75.5 vs 11.75.5 days; p0.001) and catarrhal symptoms duration (8.85.1 vs 12.04.9 days; p0.001) compared to the group without AVT. The usage of INF reduced intoxication symptoms compared with the group without AVT (8.97.5 vs 11.75.5; p0.05). Therapy with hydroxychloroquine, imidazolylethanamide pentandioic acid, and lopinavir + ritonavir combination did not affect the course of COVID-19. Most of adverse reactions were related to antibiotics. Conclusion. Umifenovir therapy and inclusion of interferon in AVT regimens was associated improvement in the clinical manifestation of the disease among patients.


  • Hepatitis C disease burden in the Russian Federation: from the real-life situation to strategy

    by V.P. Chulanov, V.N. Gorodin, O.I. Sagalova, M.R. Ivanova, Nalchik Center For The Prevention And Control Of Aids And Infectious Diseases, I.E. Kravchenko, A.I. Simakova, I.N. Tragira, V.A. Khabudaev, Irkutsk Irkutsk Regional Infectious Diseases Clinical Hospital, et al.

    Objective. To model the current and future impact of the chronic hepatitis C disease burden if the current treatment paradigm continues and is effective and if WHO strategy is implemented successfully. Materials and methods. A dynamic disease progression model was constructed in Microsoft Excel (Microsoft Corp., USA) in collaboration with CDA (Center for Disease Analysis, USA) similar to that used in previous studies. As no accurate data on HCV prevalence in Russia and its federal subjects is available, calculations were based on the prevalence of 2.5% and 4.1%. Results. The modelling suggests that, unless the treatment paradigm is changed, the chronic hepatitis C prevalence will remain the same, whereas the mortality and the rate of other HCV-related outcomes (HCC, decompensated cirrhosis) will more than double by 2030. Achieving WHO global strategy targets in Russia will help reduce the total number of infected individuals by 90% and the number of liver-related deaths by 65% saving >45,000 or >77,000 lives under the scenarios with 2.5% and 4.1% prevalence respectively. However, such trends will only take place if WHO strategy is implemented successfully. Conclusion. Regardless of the epidemiologic input data, elimination of HCV infection in Russia appears feasible; however, it requires financial support from the government and a range of organizational measures. Key words: HCV infection, chronic HCV infection, WHO strategy, antiviral therapy


  • Results of the prognosis on the epidemiological situation with hepatitis C depending on the strategy of antiviral therapy

    by A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of the Russian Federation, Nikolay D. Yushchuk, Oksana I. Ivakhnenko, "I.M. Sechenov First Moscow State Medical University of Ministry of Healthcare of the Russian Federation (Sechenov University)", Olga O. Znoyko, Kristina R. Dudina, Oleg V. Zayratyants, Mikhail I. Mikhaylov, Elena Yu. Malinnikova, Russian Medical Academy Of Continuing Professional Education, et al.


  • Open Access

    INDICATORS OF HEMOSTASIS IN PATIENTS WITH CHRONIC HEPATITIS C

    by N. V. Galeeva, I. E. Kravchenko

    Goal of the study is to reveal the particular features of hemostasis in patients with chronic hepatitis C in dynamics of natural course of disease. Materials and methods. The indices of hemostasis in 535 patients with chronic hepatitis C were assessed by the number of platelets, degree of their aggregation with the use of inductor of adenosine triphosphate and without it (spontaneous aggregation of platelets). Coagulative hemostasis was analyzed by the activated partial thromboplastin time, antitrombin III, prothrombin ratio, prothrombin time, fibrinogen concentration in plasma and international normalized ratio. Based on the number of Tr, typical for the disseminated intravascular coagulation syndrome, conditionally the patients were divided into 3 groups: I group - hypercoagulability; II - transient phase between hyper and hypocoagulation and III- hypocoagulation, which also included patients with liver cirrhosis. Results and discussion. Independent on the phase of disseminated intravascular coagulation syndrome, increase of aggregation of Tr with the growth of maximal amplitude was observed. The main part of studied indices of coagulative hemostasis indicated at the condition of hypocoagulation in patients with chronic hepatitis C - this is significant increase of activated partial thromboplastin time, prothrombin time, international normalized ratio and decrease of fibrinogen concentration in the studied groups by the phases of disseminated intravascular coagulation syndrome. Value of antitrombin III changed oppositely, it decreased, so that plasma hemostasis tends to the hypercoagulation. Conclusion. Under the chronic hepatitis C all phases of disseminated intravascular coagulation syndrome were observed with the disorder of thrombocytic coagulative hemostasis. There was followed up multidirectional change of hemostasis which obtained in the most cases character of delitescent course of disseminated intravascular coagulation syndrome.